Injury Recovery Research Stack

£59.99

Purity: ≥ 99%

£59.99

Injury Recovery Research Stack

Name: Injury Recovery Research Stack
Brand: Pure Grade Labs
Price: 59.99 GBP
Availability: OutOfStock

£59.99

Purity: ≥ 99%

£59.99

TENDON & LIGAMENT - Tendon, joint & tissue repair research

PROGENITOR RECRUITMENT - Repair cell mobilisation research

ANGIOGENESIS - New blood vessel formation research

CYTOPROTECTION - Oxidative stress & cell protection research

The Protocol the Research Community Has Converged On.

BPC-157 and TB-500 are the two most cited peptides in tissue repair research - and the most consistently studied together. They appear in the same protocols, the same forums, and the same literature because the research rationale for combining them is mechanistically sound. BPC-157 acts locally and intracellularly, driving angiogenesis and fibroblast activity at the injury site. TB-500 acts systemically, mobilising repair-competent cells from throughout the body via a blood-borne signalling mechanism that BPC-157 does not have.

Neither compound replaces the other. BPC-157 is the more studied of the two - with over 30 years of published preclinical research across tendon, ligament, bone, muscle, GI, and vascular tissue, culminating in a 2025 systematic review in HSS Journal characterising its orthopaedic research evidence. TB-500 is the broader, systemically distributed half of the protocol - Thymosin Beta-4, the naturally occurring peptide released by platelets at injury sites, synthesised here to research-grade purity.

Bacteriostatic water is included. Both vials require reconstitution and the 10ml volume covers the full stack with room to spare. No additional sourcing required before your protocol begins.

BPC-157 (Body Protection Compound 157)

Synthetic pentadecapeptide (15 amino acids) isolated from human gastric juice by Sikiric et al., 1993. Known as "stable" for its resistance to enzymatic degradation compared to naturally occurring gastric peptides. Over 30 years of preclinical research across tendon, ligament, bone, muscle, vascular, and gastrointestinal tissue models. Mechanism: VEGFR2-PI3K-Akt-eNOS and Src-caveolin-1 pathway activation drives angiogenesis, fibroblast migration and survival, collagen organisation, and cytoprotection against oxidative stress. As of 2025, a systematic review in HSS Journal characterised BPC-157 as having compelling preclinical evidence for orthopaedic and sports medicine research applications, with early human pilot data in knee, bladder, and IV safety studies.

TB-500 (Thymosin Beta-4 Synthetic)

Synthetic form of Thymosin Beta-4 (TB4) - a naturally occurring 43-amino-acid peptide found in virtually all mammalian cells, concentrated in platelets and released into wound fluid at sites of injury. TB4 is the primary regulator of G-actin sequestration - controlling the intracellular pool of actin monomers available for cell migration. It is also a systemic, blood-borne signal: platelets carry and release TB4 throughout the circulation, enabling repair-competent progenitor cells at distal sites to be recruited to an injury. This systemic reach is the mechanistic property that distinguishes TB-500 from BPC-157 and is why the two are studied together: BPC-157 acts at the injury site, TB-500 recruits reinforcements to it.

Included

Bacteriostatic Water 10ml - both BPC-157 and TB-500 are supplied as lyophilised powder requiring reconstitution before use. The included 10ml BAC water vial is sufficient for the full stack. Sold separately at £6.99 - included here so your protocol is complete from day one. No separate order needed.

BPC-157 Sequence (15 AA / Pentadecapeptide): H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH - MW: 1,419.6 g/mol - CAS: 137525-51-0

TB-500 / Thymosin Beta-4 Sequence (43 AA): Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-NH2 - MW: 4,963.5 g/mol - CAS: 77591-33-4

BPC-157 MW: 1,419.6 g/mol

TB-500 MW: 4,963.5 g/mol

BPC-157 CAS: 137525-51-0

TB-500 CAS: 77591-33-4

2025 | HSS Journal | Systematic Review

Systematic review characterises BPC-157's mechanism and 30-year preclinical evidence base across orthopaedic and sports medicine applications

Vasireddi et al. conducted a systematic review of BPC-157 literature from database inception to June 2024 across PubMed, Cochrane, and Embase, specifically from an orthopaedic and sports medicine research perspective. The review formally characterised BPC-157's mechanism via VEGFR2-PI3K-Akt-eNOS and Src-caveolin-1 signalling pathways - the most comprehensive mechanistic characterisation of BPC-157 in an English-language systematic review to date. Preclinical evidence was documented across fracture healing, tendon ruptures, ligament tears, and skeletal muscle injuries across multiple animal models. The authors concluded that the breadth and consistency of preclinical data is compelling, while identifying large-scale human RCTs as the significant remaining evidence gap. Human data at the time of review was limited to small pilot studies in knee pain (intra-articular administration), interstitial cystitis, and IV pharmacokinetics. This review represents the most current and authoritative synthesis of the BPC-157 orthopaedic research evidence available.

Vasireddi N, et al. HSS J. 2025:15563316251355551. PubMed →

2011 | Journal of Applied Physiology | In Vitro

BPC-157 accelerates tendon fibroblast outgrowth, enhances migration, and confers cytoprotection against oxidative stress

Chang et al. examined BPC-157's effects using rat Achilles tendon explant cultures and isolated tendon fibroblasts. BPC-157 produced significantly accelerated outgrowth from tendon explants and a marked, dose-dependent increase in fibroblast migration velocity in scratch-wound assays. The critical finding was the cytoprotection data: when fibroblasts were exposed to hydrogen peroxide (simulating the oxidative environment of acutely injured tissue), BPC-157-treated cells survived at significantly higher rates than controls. This suggests BPC-157 is not only stimulating the activity of tendon fibroblasts but protecting their survival in the oxidative conditions that are a normal feature of the early injury environment - a property that directly addresses one of the reasons injured tissue struggles to repair without intervention. The study also confirmed BPC-157 upregulates multiple growth factor receptors (VEGFR2, FGFR1) on tendon fibroblast surfaces.

Chang CH, et al. J Appl Physiol. 2011;110(3):774-780. PubMed →

2010 | Journal of Cell Science | In Vitro / Animal

Thymosin Beta-4 activates epicardial progenitor cells and drives systemic cardiac repair through actin dynamics and blood-borne distribution

Smart et al. demonstrated that TB4 activates dormant epicardial progenitor cells and directs them to migrate into damaged cardiac tissue in a mouse infarction model. Critically, the study characterised TB4's systemic distribution mechanism: released by activated platelets and distributed through the bloodstream, TB4 reaches progenitor cell populations that are not located at the injury site itself. Treated animals showed measurable improvement in cardiac function and enhanced myocardial regeneration. The actin-sequestration mechanism - TB4 sequesters G-actin, maintaining the pool available for rapid F-actin polymerisation when cells are directed to migrate - was characterised as the cellular basis for progenitor cell mobilisation. This systemic, blood-borne mechanism is what makes TB-500 the long-range component of this stack: where BPC-157 creates the signalling environment at the injury site, TB-500 recruits cells to it from throughout the system.

Smart N, et al. J Cell Sci. 2010;123(Pt 8):1229-1237. PubMed →

2016 | Muscles, Ligaments and Tendons Journal | Animal Study

BPC-157 accelerates healing of transected Achilles tendon in rat model - improved biomechanical properties and organisation at 4 weeks

Staresinic et al. investigated BPC-157 in a surgically transected rat Achilles tendon model - one of the most reproducible and clinically relevant injury models in tendon research. At 4 weeks post-transection, BPC-157-treated tendons demonstrated significantly improved tendon organisation by histological assessment, increased collagen fibre alignment, and superior biomechanical properties (load to failure and stiffness) compared to controls. The treated group also showed earlier and more robust vascular ingrowth into the repair tissue - consistent with the VEGFR2-mediated angiogenic mechanism documented in cell culture studies. This study is significant because it documents BPC-157's effects on a structural, load-bearing outcome measure (biomechanical properties) rather than only cellular or molecular endpoints, bridging the gap between mechanism and tissue-level function in the injury model.

Staresinic M, et al. Muscles Ligaments Tendons J. 2003;3(1):34-43. PubMed →

2012 | Annals of the New York Academy of Sciences | Review / Mechanism

Thymosin Beta-4 promotes wound healing through actin dynamics, anti-inflammation, and progenitor cell mobilisation across multiple tissue types

Goldstein et al. reviewed the accumulated mechanistic and preclinical evidence for Thymosin Beta-4 in tissue repair, summarising data across skin, cardiac, corneal, and musculoskeletal injury models. The review characterised TB4's three core mechanisms: G-actin sequestration enabling cell migration, anti-inflammatory activity via downregulation of NFkB and inflammatory cytokines, and progenitor cell activation via Wnt and PINCH signalling. Clinical data reviewed included a Phase II study in venous stasis ulcers (topical TB4) and early-phase data in cardiac repair. The review explicitly noted that TB4's systemic distribution as a platelet-released factor makes it distinct from locally acting growth factors - reinforcing why it is studied as a complement to BPC-157 rather than a replacement for it. The breadth of tissue types studied (not limited to soft tissue injury) confirmed TB4's research applicability across the injury spectrum.

Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Ann N Y Acad Sci. 2012;1270:66-76. PubMed →

Every Injury Recovery Stack ships with a batch-specific Certificate of Analysis from an independent third-party analytical laboratory, covering both BPC-157 and TB-500. The COA confirms identity, purity by HPLC, and absence of contaminants for your specific batch. This is not a shared or generic document - it is linked to your batch number.

Both peptides are supplied as lyophilised (freeze-dried) solids. Storage specifications apply to both BPC-157 and TB-500 unless otherwise noted.

Temperature: -20°C Long-term storage. For short-term use (up to 4 weeks), 2-8°C is acceptable.

Light Sensitivity: Light-Sensitive. Store in original opaque vial. Avoid direct UV or prolonged exposure to light.

Shelf Life: 24 Months. Lyophilized, sealed, stored at -20°C. Batch expiry printed on vial label.

Allow sealed vials to reach room temperature before opening to minimise moisture introduction. Bacteriostatic water is supplied ready to use - no preparation required.
Use the included bacteriostatic water as reconstitution solvent for both compounds. Add solvent slowly down the inside wall of the vial - do not inject directly onto the lyophilised cake.
Gently swirl each vial until fully dissolved. Do not vortex or shake vigorously. Both compounds dissolve readily in BAC water.
Once reconstituted, store each vial at 2-8°C. Use within 28 days. Do not freeze reconstituted solution.
Discard if solution appears cloudy, discoloured, or contains particulate matter.

BPC-157 and TB-500 supplied by Pure Grade Labs are intended exclusively for in vitro research and laboratory use. These products are not approved for human or veterinary use by any regulatory authority, including the FDA, MHRA, TGA, or EMA.

These products are not drugs, medicines, or supplements and must not be used as such.
BPC-157 was classified by the FDA as a Category 2 bulk drug substance in September 2023, restricting its use in compounded medications in the United States. This does not affect its research-use status in the UK.
Pure Grade Labs makes no claims regarding therapeutic or clinical efficacy in humans for either compound.
Both BPC-157 and TB-500 are prohibited in sport by WADA under the S0 Unapproved Substances category. Athletes subject to drug testing must not use these products.
These products must not be administered to humans or animals outside of a licensed research context.
Purchasers are solely responsible for compliance with all applicable laws and regulations in their jurisdiction.

All research summaries and study citations on this page are provided for informational context only and do not constitute medical advice, endorsement of any treatment, or recommendation for human use.